Mission magazine banner

Drug trial helps woman cheat death for five years

March 2009

by Karen Stamm

Carolyn Boone
Carolyn Boone travels from Dallas to the CTRC every three weeks for intravenous treatment. "I continue to live life one day at a time."
In 2003, after Dallas resident Carolyn Boone had her hysterectomy, doctors discovered a huge and fast-growing tumor, diagnosed as mullerian sarcoma. It spread to her liver and lungs. Her oncologistís prognosis: The cancer would not respond to chemotherapy or radiation and Boone had maybe a year to live. He referred her to the CTRC at the UT Health Science Center San Antonio for an experimental study.

Five years later, Boone is still alive, and a patient of Dr. Monica Mita. The drug that stabilized her cancer is known as Agent AP23573, which regulates normal cell growth and slows or stops the growth of cancer cells. The drug has progressed to the third of four phases of testing.

"Carolyn Booneís story is an inspiration for other patients and care providers," Dr. Mita said. "Her experience is what we would like to see for all patients with advanced cancer - significant and durable response with a normal quality of life."

How to enroll in a clinical study

During the past five years, more than 3,000 patients have been treated in new drug studies at the CTRC at the UT Health Science Center San Antonio. For some patients, these treatments offer hope, when before, there was none.

To learn about enrolling in a clinical study, contact the CTRCís Clinical Studies Referral Office.

Phone: (210) 450-5798
Fax: (210) 616-5844
E-mail: onctrial@idd.org


Related Stories

Husband-and-wife oncology team: Never give up!


More stories:

Read current stories



Previous Issues

Current Issue (PDF)


Email us

HSC News

Make a Gift

University Home

UT Health Science Center
7703 Floyd Curl Dr.
San Antonio, Texas

© 2002 - 2015 UTHSCSA
Office of Communications
All rights reserved.

Links provided from UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.

Updated 12/11/14